5736-91-4Relevant articles and documents
First columnar rufigallol liquid crystals with high fluorescence at aggregated states
Zhang, Xiaoyi,Qin, Wenwei,Cheng, Bifeng,Guo, Hongyu,Yang, Fafu
, (2020)
The design and synthesis of columnar liquid crystals with high fluorescence at aggregated states (eliminating the ACQ effect) was an important challenge in the field of liquid crystalline materials. In this work, the first rufigallol columnar liquid crystals with AIE groups were prepared and exhibited good fluorescence in aggregated states. A series of diphenylacrylonitrile-rufigallol-diphenylacrylonitrile trimers was designed and prepared in 70–78% yields. They showed the ordered hexagonal columnar liquid crystals based on the induction of planar rufigallol structures. They also exhibited the good fluorescence in aggregated states with the fluorescence quantum yields of 0.21–0.26 based on the AIE effect of diphenylacrylonitrile units. The length of bridging alkyl chains between rufigallol and diphenylacrylonitrile units contributed to decrease the mesophase transition temperature and increase the fluorescence quantum yields.
1,3-Oxazine-2-one derived dual-targeted molecules against replicating and non-replicating forms of Mycobacterium tuberculosis
Velappan, Anand Babu,Kesamsetty, Dhanunjaya,Datta, Dhrubajyoti,Ma, Rui,Hari, Natarajan,Franzblau, Scott G.,Debnath, Joy
supporting information, (2020/10/02)
The high mortality rate and increasing prevalence of resistant Mtb are the major concerns for the Tuberculosis (TB) treatment in this century. To curtail the prevalence of resistant Mtb, we have prepared 1,3-oxazine-2-one based dual targeted molecules. Compound 67 and 68 were found to be equally active against replicating and non-replicatiing form of Mtb (MICMABA 3.48 and 2.97 μg/ml; MICLORA 2.94 and 2.15 μg/ml respectively). They had found to suppress the biosynthesis of alfa, methoxy and keto-mycolate completely, as well as inhibit enzymatic activity of MenG (IC50 = 9.11 and 6.25 μg/ml respectively for H37Ra; IC50 = 11.76 and 10.88 μg/ml respectively for M smegmatis).
Anticancer, antimicrobial activities of quinoline based hydrazone analogues: Synthesis, characterization and molecular docking
Katariya, Kanubhai D,Shah, Shailesh R.,Reddy, Dushyanth
supporting information, (2019/11/26)
Based on the biologically active heterocycle quinoline, a series (18a-p) of quinoline hydrazone analogues were prepared, starting from 6-bromo/6-chloro-2-methyl-quinolin-4-yl-hydrazines. For all the newly synthesized compounds cytotoxic activities were carried out at the National Cancer Institute (NCI), USA, against full NCI 60 human cancer cell lines. Amongst all the tested compounds, nine compounds (18b, 18d, 18e, 18f, 18g, 18h, 18i, 18j, 18l) exhibited important anti-proliferative activity at 10 μM concentration and were further screened at 10-fold dilutions of five different concentrations (0.01, 0.1, 1, 10 and 100 μM) with GI50 values ranging from 0.33 to 4.87 μM and LC50 values ranging from 4.67 μM to >100j μM. Further, the mean values of GI50, TGI and LC50 of the most potent compound 18j were compared with the clinically used anticancer agents bendamustine and chlorambucil, revealed that the quinolyl hydrazones holds promise as a potential anticancer agents. Further all the newly prepared compounds were screened for their antimicrobial activity. All the quinolyl hydrazones displayed good to excellent antimicrobial activity with MIC values ranging from 6.25 to 100 μg/mL against the tested pathogenic strains. Molecular docking of the synthesized compounds into the active binding site of human DNA topoisomerase I (htopoI) was carried out to predict the binding mode to the DNA topoisomerase I inhibitors. Hopefully in future, compounds based on quinoline core could be used as a lead compounds for designing new anticancer agents.
